Source-grounded facts extracted from Contineum Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Contineum Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $14.5 million.
“million, a 20 percent increase from the first quarter of 2025. The increase was primarily driven by higher stock-based compensation and employee-related costs. • Net loss was $14.5 million for the three months ended March 31, 2026, as compared to $16.0 million for the first quarter of 2025.”
Diego Miralles, M.D. was appointed as Director at Contineum Therapeutics, Inc..
“On March 14, 2025, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Diego Miralles, M.D. as a member of its Board, effective March 14, 2025.”
Sarah Boyce was appointed as Class I Director and Chair of Nominating and Corporate Governance Committee at Contineum Therapeutics, Inc..
“On June 21, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Sarah Boyce as a member of its Board, effective June 24, 2024.”
Troy Ignelzi was appointed as Class I Director and Chair of Audit Committee at Contineum Therapeutics, Inc..
“On May 20, 2024, the board of directors (the “Board”) of Contineum Therapeutics, Inc. (the “Company”) appointed Troy Ignelzi as a member of its Board, effective immediately.”
Contineum Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
“today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.”
Contineum Therapeutics, Inc.: Adopted amended and restated bylaws effective upon IPO closing, eliminating stockholder action by written consent and establishing procedures for stockholder proposals and director nominations (effective 2024-04-09).
“Effective as of April 9, 2024 the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.”
Contineum Therapeutics, Inc.: Amended and restated certificate of incorporation in connection with IPO, including changes to authorized stock, board classification, and exclusive forum provisions (effective 2024-04-09).
“On April 9, 2024, Contineum Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering (the “IPO”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.